Long-acting drugs and formulations for the treatment and prevention of HIV infection

医学 药理学 整合酶抑制剂 人类免疫缺陷病毒(HIV) 药品 逆转录酶抑制剂 利比韦林 抗药性 单克隆抗体 临床试验 杜鲁特格拉维尔 病毒学 免疫学 抗体 内科学 病毒载量 抗逆转录病毒疗法 生物 微生物学
作者
Charles W. Flexner,Andrew Owen,Marco Siccardi,Susan Swindells
出处
期刊:International Journal of Antimicrobial Agents [Elsevier BV]
卷期号:57 (1): 106220-106220 被引量:109
标识
DOI:10.1016/j.ijantimicag.2020.106220
摘要

Long-acting and extended-release formulations represent one of the most important approaches to improving the treatment and prevention of chronic HIV infection. Long-acting small molecules and monoclonal antibodies have demonstrated potent anti-HIV activity in early- and late-stage clinical trials. Strategies to manage toxicity and falling drug concentrations after missed doses, as well as primary and secondary resistance to current drugs and monoclonal antibodies are important considerations. Long-acting injectable nanoformulations of the integrase inhibitor cabotegravir and the non-nucleoside reverse transcriptase inhibitor rilpivirine were safe, well tolerated and efficacious in large randomised phase 3 studies. Regulatory approval for this two-drug combination for HIV maintenance therapy was granted in Canada in 2020 and is expected in the USA during 2021. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (islatravir) is a novel nucleoside reverse transcriptase inhibitor in clinical development as a long-acting oral drug and as a long-acting subcutaneous polymer implant. GS-6207 is a novel HIV capsid inhibitor that is injected subcutaneously every 3 months. Broadly-neutralising monoclonal antibodies have potent antiviral activity in early human trials, however there is substantial baseline resistance and rapid development of resistance to these antibodies if used as monotherapy. Limitations of these antiretroviral approaches include management of toxicities and prevention of drug resistance when these drugs are discontinued and drug concentrations are slowly reduced over time. These approaches appear to be especially attractive for patients complaining of pill fatigue and for those experiencing HIV-associated stigma. As these formulations are shown to be safe, well tolerated and economical, they are likely to gain broader appeal.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
俟天晴完成签到,获得积分10
1秒前
CipherSage的应助被科研通管家采纳,获得10
1秒前
工作热情仔的应助被General采纳,获得20
1秒前
1秒前
斯文败类的应助被科研通管家采纳,获得10
1秒前
1秒前
1秒前
Pupupapa发布了新的文献求助10
2秒前
晚风发布了新的文献求助10
2秒前
2秒前
我爱我家完成签到 ,获得积分10
3秒前
haan发布了新的文献求助30
3秒前
4秒前
Stella发布了新的文献求助10
4秒前
晚荔酪发布了新的文献求助30
5秒前
zero完成签到 ,获得积分10
6秒前
6秒前
6秒前
柚子完成签到 ,获得积分10
6秒前
6秒前
6秒前
小一班www完成签到,获得积分10
7秒前
时尚白凡完成签到 ,获得积分10
7秒前
8秒前
8秒前
latata完成签到 ,获得积分10
8秒前
共享精神的应助被haan采纳,获得10
8秒前
兔飞发布了新的文献求助10
8秒前
晚风发布了新的文献求助10
9秒前
Li发布了新的文献求助10
9秒前
liu发布了新的文献求助200
10秒前
yyc完成签到,获得积分10
10秒前
10秒前
10秒前
Ava的应助被liuze采纳,获得10
11秒前
cwm发布了新的文献求助10
11秒前
坤子完成签到,获得积分10
12秒前
12秒前
chenzhaoyang发布了新的文献求助10
12秒前
香风智乃完成签到 ,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593